New York, NY – According to filings with the U.S. Securities and Exchange Commission, Equilibre BioPharmaceuticals is raising $25,000,000.00 in new funding. Sources indicate as part of senior management Chief Operating Officer, Steven Gordon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Equilibre BioPharmaceuticals
Equilibre Biopharmaceuticals Corp. was established as an innovative biopharmaceutical company focused on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. Our approach is to leverage our biopharmaceutical industry expertise to further expand our portfolio of product opportunities. Our business strategy is designed to be flexible and nimble, which allows us to develop a broad array of new therapies with clinical and commercial potential. Were driven by our passion to help patients. In pursuit of the betterment of patients, we encourage and promote collaboration and teamwork among our employees and those of our partners to potentially accelerate drug developments and foster best practices.

To learn more about Equilibre BioPharmaceuticals, visit http://eqneuro.com/

Contact:
Steven Gordon, Chief Operating Officer
332-400-0300

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved